文献速递免疫规划

肯尼亚通过手机短信提醒和激励措施改善儿童免疫接种覆盖率和及时性(M-SIMU):一项整群随机对照试验

Mobile phone-delivered reminders and incentives to improve childhood immunisation coverage and timeliness in Kenya (M-SIMU): a cluster randomised controlled trial.
PubMed 文献 · Lancet Glob Health · 2017-01-01

该整群随机对照试验在肯尼亚152个村庄纳入2018名看护者及其婴儿,随机分为对照组、仅短信提醒组、短信加75肯尼亚先令激励组和短信加200肯尼亚先令激励组。结果显示短信加200肯尼亚先令组12月龄完全免疫率显著高于对照组(相对风险1.09,95%CI 1.02-1.16,p=0.014)。在基础免疫覆盖率高的环境中,短信提醒联合激励措施显著改善了免疫覆盖率和及时性。

要点

  • 短信加200肯尼亚先令组12月龄完全免疫率显著高于对照组(相对风险1.09,95%CI 1.02-1.16,p=0.014)。
  • 短信加75肯尼亚先令组和仅短信组完全免疫率与对照组相比未达统计学显著。
  • 在基础免疫覆盖率高的环境中,短信提醒联合激励措施显著改善免疫覆盖率和及时性。

核心结论

  • 在基础免疫覆盖率高的环境中,短信提醒联合激励措施显著改善了免疫覆盖率和及时性。
  • 鉴于全球免疫覆盖率停滞在约85%,使用激励措施可能是覆盖剩余15%的一种选择。

研究设计与样本

  • 整群随机对照试验,村庄被随机均匀分配至四组:对照组、仅短信提醒组、短信加75肯尼亚先令激励组和短信加200肯尼亚先令激励组(85肯尼亚先令=1美元)。
  • 纳入标准为看护者有一个小于5周且尚未接种第一剂五联疫苗的儿童。
  • 2013年10月14日至2014年10月17日期间,从152个村庄纳入2018名看护者及其婴儿:对照组n=489,仅短信组n=476,短信加75肯尼亚先令组n=562,短信加200肯尼亚先令组n=491。
  • 干预组在预定五联疫苗和麻疹疫苗接种访视前收到短信提醒;激励组儿童若及时接种(在预定日期2周内接种)还可获得金钱。
  • 主要结局为12月龄时完全免疫(接种卡介苗、三剂脊灰疫苗、三剂五联疫苗和麻疹疫苗)的儿童比例,采用对数二项回归和广义估计方程分析以考虑整群内相关性。

主要发现

  • 成功随访的1600名儿童中,1375名(86%)在12月龄时达到主要结局(完全免疫):对照组296/360(82%),仅短信组332/388(86%),短信加75肯尼亚先令组383/446(86%),短信加200肯尼亚先令组364/406(90%)。
  • 短信加200肯尼亚先令组儿童在12月龄时达到完全免疫的可能性显著高于对照组(相对风险1.09,95%CI 1.02-1.16,p=0.014)。

局限性

  • 看护者和访谈者未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As mobile phone access continues to expand globally, opportunities exist to leverage these technologies to support demand for immunisation services and improve vaccine coverage. We aimed to assess whether short message service (SMS) reminders and monetary incentives can improve immunisation uptake in Kenya. METHODS: In this cluster-randomised controlled trial, villages were randomly and evenly allocated to four groups: control, SMS only, SMS plus a 75 Kenya Shilling (KES) incentive, and SMS plus 200 KES (85 KES = USD$1). Caregivers were eligible if they had a child younger than 5 weeks who had not yet received a first dose of pentavalent vaccine. Participants in the intervention groups received SMS reminders before scheduled pentavalent and measles immunisation visits. Participants in incentive groups, additionally, received money if their child was timely immunised (immunisation within 2 weeks of the due date). Caregivers and interviewers were not masked. The proportion of fully immunised children (receiving BCG, three doses of polio vaccine, three doses of pentavalent vaccine, and measles vaccine) by 12 months of age constituted the primary outcome and was analysed with log-binomial regression and General Estimating Equations to account for correlation within clusters. This trial is registered with ClinicalTrials.gov, number NCT01878435. FINDINGS: Between Oct 14, 2013, and Oct 17, 2014, we enrolled 2018 caregivers and their infants from 152 villages into the following four groups: control (n=489), SMS only (n=476), SMS plus 75 KES (n=562), and SMS plus 200 KES (n=491). Overall, 1375 (86%) of 1600 children who were successfully followed up achieved the primary outcome, full immunisation by 12 months of age (296 [82%] of 360 control participants, 332 [86%] of 388 SMS only participants, 383 [86%] of 446 SMS plus 75 KES participants, and 364 [90%] of 406 SMS plus 200 KES participants). Children in the SMS plus 200 KES group were significantly more likely to achieve full immunisation at 12 months of age (relative risk 1·09, 95% CI 1·02-1·16, p=0·014) than children in the control group. INTERPRETATION: In a setting with high baseline immunisation coverage levels, SMS reminders coupled with incentives significantly improved immunisation coverage and timeliness. Given that global immunisation coverage levels have stagnated around 85%, the use of incentives might be one option to reach the remaining 15%. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Gibson DG, Ochieng B, Kagucia EW, et al. Mobile phone-delivered reminders and incentives to improve childhood immunisation coverage and timeliness in Kenya (M-SIMU): a cluster randomised controlled trial. Lancet Glob Health. 2017. PMID: 28288747. doi:10.1016/S2214-109X(17)30072-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。